Pharma Deals Review, Vol 2007, No 85 (2007)

Font Size:  Small  Medium  Large

Novacea Licences Cancer Therapy to Schering-Plough for US$452 M

Business Review Editor

Abstract


Novacea and Schering-Plough entered into worldwide license agreement for Novacea’s Asentar™ (DN-101), which is phase 3 clinical trials for treating prostate cancer. The deal would worth up to US$452 M to Novacea.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.